Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trastuzumab and hyaluronidase-oysk
- Development stage
- Approved
- Lead developer
- Genentech
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
Trastuzumab and hyaluronidase-oysk is a fixed-dose combination of two agents for subcutaneous injection. It contains trastuzumab, a recombinant humanized monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2; also known as receptor tyrosine-protein kinase erbB-2), and hyaluronidase-oysk, a recombinant human hyaluronidase PH20 enzyme. Trastuzumab binds to HER2 on cancer cells, blocking their ability to send growth signals and mediating antibody-dependent cellular cytotoxicity (ADCC) against HER2-overexpressing tumor cells. Hyaluronidase temporarily breaks down the extracellular matrix component hyaluronan at the injection site, increasing tissue permeability and facilitating rapid absorption of trastuzumab into systemic circulation. This formulation allows for faster subcutaneous administration compared to intravenous trastuzumab. The drug is approved for use in adults with HER2-positive breast cancer—both early-stage (as adjuvant therapy) and metastatic settings—either in combination with other chemotherapies or as monotherapy after prior treatments[1][3][4][6].
- Brand names
- Herceptin Hylecta
- Other names
- trastuzumab-oysk and hyaluronidaseHerceptin HYLECTA
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on trastuzumab and hyaluronidase-oysk.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trastuzumab and hyaluronidase-oysk.